SRPT Sarepta Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 873303 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-18.9%
TTM net income YoY19.4%
TTM EPS YoY19.9%
Revenue 3-yr CAGR21.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2.5%
Net margin-5.9%
FCF margin9.0%
EBITDA margin-0.9%
Returns
ROE-7.6%
ROA-3.4%
ROIC (approx.)-2.5%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets51.7%
Debt / equity0.66x
Current ratio3.46x
Interest coverage0.62x
Cash quality & payout
Operating cash flow / net income-1.62x
Accruals ratio-9.0%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.20B | $1.90B | $1.24B | $933.01M | $701.89M |
| Cost of revenue | $25.50M | — | — | — | — |
| Gross profit | $2.17B | — | — | — | — |
| R&D expense | $1.52B | $804.52M | $877.39M | $877.09M | $771.18M |
| SG&A expense | $491.72M | $557.87M | $481.87M | $451.42M | $282.66M |
| Operating income | -$699.78M | $218.08M | -$267.82M | -$536.20M | -$459.71M |
| Interest expense | -$38.14M | -$18.39M | -$22.01M | -$53.25M | $63.52M |
| Pretax income | -$702.23M | $260.77M | -$520.10M | -$689.96M | -$418.95M |
| Income tax | $11.19M | $25.54M | $15.88M | $13.53M | -$168,000 |
| Net income | -$713.41M | $235.24M | -$535.98M | -$703.49M | -$418.78M |
| EBITDA | -$655.26M | $255.81M | -$223.43M | -$494.34M | -$421.69M |
| EPS (basic) | -7.13 | 2.47 | -5.80 | -8.03 | -5.15 |
| EPS (diluted) | -7.13 | 2.34 | -5.80 | -8.03 | -5.15 |
| Weighted avg. shares (diluted) | 100.12M | 107.88M | 92.40M | 87.56M | 81.26M |
| Balance sheet | |||||
| Cash & equivalents | $801.28M | $1.12B | $428.43M | $966.78M | $2.12B |
| Short-term investments | $138.37M | $251.78M | $1.25B | $1.02B | $0 |
| Receivables | $398.23M | $601.99M | $400.33M | $214.63M | $152.99M |
| Inventory | $914.74M | $749.96M | $322.86M | $203.97M | $186.21M |
| Current assets | $2.54B | $3.07B | $2.58B | $2.56B | $2.60B |
| PP&E, net | $345.12M | $340.34M | $227.15M | $180.04M | $191.16M |
| Intangibles | $28.95M | $26.89M | $29.62M | $7.58M | $14.24M |
| Total assets | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B |
| Current liabilities | $1.10B | $731.68M | $653.66M | $619.60M | $452.73M |
| Short-term debt | $0 | $0 | $105.48M | $0 | — |
| Long-term debt | $828.97M | $1.14B | $1.24B | $1.54B | $563.67M |
| Total debt | $828.97M | $1.14B | $1.34B | $1.54B | $563.67M |
| Total liabilities | $2.21B | $2.44B | $2.41B | $2.74B | $2.22B |
| Shareholders' equity | $1.14B | $1.53B | $859.34M | $384.95M | $928.01M |
| Net debt | $27.69M | $18.54M | $915.05M | $577.51M | -$1.55B |
| Shares outstanding | 104.96M | 96.90M | 93.73M | 87.95M | 87.13M |
| Cash flow statement | |||||
| Operating cash flow | -$205.48M | -$205.79M | -$500.99M | -$325.35M | -$443.17M |
| Capital expenditure | $101.97M | $136.96M | $76.11M | $30.82M | $38.49M |
| Free cash flow | -$307.45M | -$342.74M | -$577.10M | -$356.17M | -$481.66M |
| Investing cash flow | $69.64M | $755.56M | -$165.80M | -$1.05B | $495.41M |
| Financing cash flow | -$168.34M | $124.81M | $125.00M | $232.51M | $561.57M |
| Depreciation & amortization | $44.52M | $37.72M | $44.40M | $41.86M | $38.02M |
| Stock-based compensation | $123.40M | $184.30M | $182.51M | $233.02M | $113.94M |
| Share buybacks | $25.01M | $0 | $0 | — | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.